Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIOSynVax Universal Influenza vaccine
- Development stage
- Preclinical
- Lead developer
- DIOSynVax
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal, Intramuscular (potentially; Primary Focus On Mucosal/intranasal Delivery)
01
Overview
The DIOSynVax Universal Influenza vaccine is an investigational next-generation universal influenza vaccine developed by DioSynVax, a company based at the University of Cambridge. The vaccine is designed to provide broad protection against multiple influenza virus strains, including all major clades of the H5 avian flu subtype. It utilizes advanced artificial intelligence-driven antigen design and is being developed as an mRNA-based platform, with potential for mucosal (intranasal) delivery to enhance uptake and immune response. The technology aims for rapid scalability and global distribution, targeting both seasonal and pandemic influenza threats[2][4][10]. As of 2025, it remains in preclinical development.
- Brand names
- DIOSynVax Universal Influenza vaccine
- Other names
- Universal Influenza Vaccine (DIOSynVax)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on DIOSynVax Universal Influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIOSynVax Universal Influenza vaccine.